ASCO 2023 - good news for CHOSA
· Immuno Oncology with PD1 inhibitors successful in NSCLC in combination with cisplatin. · CHOSA’s DRP has the potential to turn this combination into precision therapy. CHOSA Oncology AB ("CHOSA") presents highlights from the American Society of Clinical Oncology (ASCO) in a video on the homepage.Listen to CEO Peter Buhl Jensen’s presentation here Previously communicated abstract on LiPlaCis data presented at ASCO can be found here .